gms | German Medical Science

57th Annual Meeting of the German Society of Neurosurgery
Joint Meeting with the Japanese Neurosurgical Society

German Society of Neurosurgery (DGNC)

11 - 14 May, Essen

NCAM-140 is down-regulated in human gliomas with increasing WHO grade – final results

NCAM-140 sinkt mit steigenden WHO-Grad in humanen Gliomen – finale Ergebnisse

Meeting Abstract

  • corresponding author S.A. Kuhn - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • K. Ebmeier - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • R. Reichart - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • M. Brodhun - Klinik für Pathologie, Klinikum der Friedrich-Schiller-Universität Jena
  • C. Ewald - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • P. Dünisch - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • J. Koblitz - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena
  • R. Kalff - Klinik für Neurochirurgie, Klinikum der Friedrich-Schiller-Universität, Jena

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 57. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie. Essen, 11.-14.05.2006. Düsseldorf, Köln: German Medical Science; 2006. DocP 05.59

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dgnc2006/06dgnc276.shtml

Published: May 8, 2006

© 2006 Kuhn et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Gliomas interact with their microenvironment. NCAM-140 is one of the best known interaction molecules. It is expressed in neurons and glia, but also in gliomas. We want to investigate NCAM-140-expression in human gliomas.

Methods: Staining was performed on sections of 171 human gliomas and 39 other intracranial tumors with polyclonal antibodies to NCAM-140. Morphology was characterized by hematoxylin/eosin. Autopsy material of 20 patients served as control. Densitometry was done with Image 1.41 for Mac computers. SPSS version 13.0 was used for statistics.

Results: With the first statistically evaluated 92 tumors, we confirmed our recent results that have shown a down-regulation of NCAM-140 expression in human gliomas of different histology with increasing tumor grade according to WHO. Initial macroscopy and microscopy enabled visualization of major differences of NCAM-140-expression status. This was confirmed by densitometry. Mean density of NCAM-140 immunoreactivity was 152.44 (±5.12) in control brain tissue and was significantly different from all other glioma entities. Mean densities of 144.01 (±4.82) in low-grade glioma and 142.57 (±6.07) in anaplastic glioma were significantly different from each other, and were different from mean density of NCAM-140 immunoreactivity in glioblastomas of 140.51 (±2.62) with statistical significance. Mixed gliomas overtake an intermediate position with respect to their NCAM-140-positivity. Four glioblastomas out of 22 expressed unusual high amounts of NCAM-140 that can be compared with healthy brain tissue. Whether this is related to a better outcome remains to be investigated. Optic density of NCAM-140-expression in other intracranial tumors was significantly different from that of gliomas.

Conclusions: The NCAM-140-expression is inversely correlated to WHO grade in human gliomas, with the glioblastomas demonstrating negativity in the very most cases. The expression profile of NCAM-140 was typical only for gliomas and differed strictly from that of other intracranial tumors. Further studies are mandatory to correlate the NCAM-140 expression profile with the prognosis data of patients and are on the way.